PDF(Pubmed)
Abstract：
UNASSIGNED: Pancreatic acinar cell carcinoma (PACC) is rare, and its appropriate treatment remains unknown. We aim to explore the characteristics and optimal treatment of it.
UNASSIGNED: The data on clinicopathologic characteristics, molecular alteration, treatment, and survival of patients diagnosed with PACC at the Sun Yat-sen University Cancer Center from 2005 to 2020 were collected. The optimal treatment was explored by co-analyzing our results and published literatures.
UNASSIGNED: Twenty-two PACC patients were enrolled. Eight of 17 non-metastatic patients received adjuvant chemotherapy. The patients receiving fluoropyrimidine-based regimen (n = 3) had a better median disease-free survival (mDFS) than those with gemcitabine-based regimen (n = 5) (unreached vs 27 months). Eight metastatic patients received first-line chemotherapy. Four patients received second-line chemotherapy. The objective response rate (ORR) of the fluoropyrimidine-based regimen was 85.7% (6/7), much better than that of the gemcitabine-based regimen (0/5). One patient who had responded to the first-line FOLFIRINOX (5-fluorouracil + oxaliplatin + leucovorin + irinotecan) regimen received olaparib as maintenance treatment for 5 months with good tolerance. Thirty-one published literatures, with a total of 86 cases, were included in the co-analysis. The ORR of the first-line fluoropyrimidine-based regimen (n = 47) was higher than that of gemcitabine-based regimen (n = 39) (59.6% vs 15.3%, P < .001). Eight of 11 patients treated with the FOLFIRINOX regimen achieved partial response (PR).
UNASSIGNED: For patients with metastasis, a fluorouracil-based regimen such as FOLFIRINOX may be preferred, and maintenance treatment of poly ADP-ribose polymerase (PARP) inhibitors after effective platinum-containing treatment for breast cancer susceptibility gene (BRCA) mutation patients must be assessed.
UNASSIGNED: The data on clinicopathologic characteristics, molecular alteration, treatment, and survival of patients diagnosed with PACC at the Sun Yat-sen University Cancer Center from 2005 to 2020 were collected. The optimal treatment was explored by co-analyzing our results and published literatures.
UNASSIGNED: Twenty-two PACC patients were enrolled. Eight of 17 non-metastatic patients received adjuvant chemotherapy. The patients receiving fluoropyrimidine-based regimen (n = 3) had a better median disease-free survival (mDFS) than those with gemcitabine-based regimen (n = 5) (unreached vs 27 months). Eight metastatic patients received first-line chemotherapy. Four patients received second-line chemotherapy. The objective response rate (ORR) of the fluoropyrimidine-based regimen was 85.7% (6/7), much better than that of the gemcitabine-based regimen (0/5). One patient who had responded to the first-line FOLFIRINOX (5-fluorouracil + oxaliplatin + leucovorin + irinotecan) regimen received olaparib as maintenance treatment for 5 months with good tolerance. Thirty-one published literatures, with a total of 86 cases, were included in the co-analysis. The ORR of the first-line fluoropyrimidine-based regimen (n = 47) was higher than that of gemcitabine-based regimen (n = 39) (59.6% vs 15.3%, P < .001). Eight of 11 patients treated with the FOLFIRINOX regimen achieved partial response (PR).
UNASSIGNED: For patients with metastasis, a fluorouracil-based regimen such as FOLFIRINOX may be preferred, and maintenance treatment of poly ADP-ribose polymerase (PARP) inhibitors after effective platinum-containing treatment for breast cancer susceptibility gene (BRCA) mutation patients must be assessed.
摘要：
未经证实：胰腺腺泡细胞癌（PACC）罕见，其适当的治疗方法仍然未知。我们旨在探索其特征和最佳治疗方法。
未经授权：关于临床病理特征的数据，分子改变,治疗,收集2005年至2020年在中山大学肿瘤防治中心诊断为PACC的患者的生存率。通过共同分析我们的结果和发表的文献，探索了最佳的治疗方法。
UNASSIGNED：纳入了22例PACC患者。17名非转移性患者中有8名接受了辅助化疗。接受基于氟嘧啶的方案（n=3）的患者的中位无病生存期（mDFS）优于接受基于吉西他滨的方案（n=5）（未达到vs27个月）。八名转移性患者接受了一线化疗。4例患者接受二线化疗。基于氟嘧啶的方案的客观缓解率（ORR）为85.7％（6/7），比基于吉西他滨的方案好得多（0/5）。一名对一线FOLFIRINOX（5-氟尿嘧啶+奥沙利铂+亚叶酸+伊立替康）方案有反应的患者接受奥拉帕尼维持治疗5个月，耐受性良好。发表的31篇文献，共86例,包括在共同分析中。基于氟嘧啶的一线方案（n=47）的ORR高于基于吉西他滨的方案（n=39）（59.6％vs15.3％，P<.001)。11例接受FOLFIRINOX方案治疗的患者中有8例获得部分缓解（PR）。
未经证实：对于有转移的患者，基于氟尿嘧啶的方案，如FOLFIRINOX可能是优选的，对乳腺癌易感基因(BRCA)突变患者进行有效含铂治疗后,必须评估多聚ADP-核糖聚合酶(PARP)抑制剂的维持治疗.
未经授权：关于临床病理特征的数据，分子改变,治疗,收集2005年至2020年在中山大学肿瘤防治中心诊断为PACC的患者的生存率。通过共同分析我们的结果和发表的文献，探索了最佳的治疗方法。
UNASSIGNED：纳入了22例PACC患者。17名非转移性患者中有8名接受了辅助化疗。接受基于氟嘧啶的方案（n=3）的患者的中位无病生存期（mDFS）优于接受基于吉西他滨的方案（n=5）（未达到vs27个月）。八名转移性患者接受了一线化疗。4例患者接受二线化疗。基于氟嘧啶的方案的客观缓解率（ORR）为85.7％（6/7），比基于吉西他滨的方案好得多（0/5）。一名对一线FOLFIRINOX（5-氟尿嘧啶+奥沙利铂+亚叶酸+伊立替康）方案有反应的患者接受奥拉帕尼维持治疗5个月，耐受性良好。发表的31篇文献，共86例,包括在共同分析中。基于氟嘧啶的一线方案（n=47）的ORR高于基于吉西他滨的方案（n=39）（59.6％vs15.3％，P<.001)。11例接受FOLFIRINOX方案治疗的患者中有8例获得部分缓解（PR）。
未经证实：对于有转移的患者，基于氟尿嘧啶的方案，如FOLFIRINOX可能是优选的，对乳腺癌易感基因(BRCA)突变患者进行有效含铂治疗后,必须评估多聚ADP-核糖聚合酶(PARP)抑制剂的维持治疗.
